<DOC>
	<DOCNO>NCT02897206</DOCNO>
	<brief_summary>This prospective , single-center , randomize , placebo-controlled , double-blind clinical trial aim investigate beneficial harmful effect prophylactic use imipenem patient predict severe acute pancreatitis . All patient first attack acute pancreatitis , onset disease le 72h admission , APACHE II score ≥ 8 calculate within first 24h admission enrol .</brief_summary>
	<brief_title>Imipenem Prophylaxis Patients With Acute Pancreatitis</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Cilastatin</mesh_term>
	<criteria>diagnosis acute pancreatitis define Revised 2012 Atlanta Criteria first manifestation acute pancreatitis regardless etiology APACHE II ≥ 8 calculate within first 24 hour admission onset symptom &lt; 72 hour admission age &lt; 18 year pregnant breastfeed woman active documented infection admission concomitant antibiotic treatment antibiotic treatment present within 72 hour enrollment acute pancreatitis diagnose surgery active malignancy know immune deficiency patient chronic pancreatitis patient unwilling participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute pancreatitis</keyword>
	<keyword>Antibiotic prophylaxis</keyword>
	<keyword>Imipenem-cilastatin</keyword>
	<keyword>Infected pancreatic necrosis</keyword>
	<keyword>Infection</keyword>
	<keyword>Organ failure</keyword>
</DOC>